RVPHREVIVA PHARMACEUTICALS HOLD...

Nasdaq revivapharma.com


$ 1.30 $ -0.24 (-15.58 %)    

Tuesday, 21-May-2024 11:57:19 EDT
QQQ $ 454.82 $ 0.41 (0.09 %)
DIA $ 398.57 $ 0.09 (0.02 %)
SPY $ 530.36 $ 0.66 (0.12 %)
TLT $ 91.26 $ -0.08 (-0.09 %)
GLD $ 225.37 $ -0.53 (-0.24 %)
$ 1.54
$ 1.50
$ 0.00 x 0
$ 1.31 x 200
$ 1.25 - $ 1.50
$ 1.46 - $ 8.00
431,616
na
42.99M
$ -0.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 04-15-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-15-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-22-2021 12-31-2020 10-K
15 01-14-2021 11-30-2020 10-Q
16 10-14-2020 08-31-2020 10-Q
17 07-07-2020 05-31-2020 10-Q
18 05-04-2020 02-29-2020 10-K
19 01-10-2020 11-30-2019 10-Q
20 10-08-2019 08-31-2019 10-Q
21 07-03-2019 05-31-2019 10-Q
22 05-22-2019 02-28-2019 10-K
23 01-09-2019 11-30-2018 10-Q
24 10-11-2018 08-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reviva-provides-enrollment-update-for-its-open-label-extension-study-evaluating-brilaroxazine-in-schizophrenia

– 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia –– Brilaroxazine is generally w...

 reviva-pharmaceuticals-q1-eps-025-beats-042-estimate

Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate o...

 reviva-to-present-new-preclinical-efficacy-data-on-brilaroxazine-in-idiopathic-pulmonary-fibrosis-at-2024-ats-international-conference-in-san-diego-ca-may-17-22-2024

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical co...

 hc-wainwright--co-reiterates-buy-on-reviva-pharmaceuticals-maintains-20-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains ...

 benchmark-reiterates-speculative-buy-on-reviva-pharmaceuticals-maintains-17-price-target

Benchmark analyst Bruce Jackson reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Speculative Buy and maintains $17 pri...

 reviva-pharmaceuticals-q4-eps-035-misses-032-estimate

Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate...

 reviva-to-present-recover-phase-3-clinical-trial-data-for-brilaroxazine-in-schizophrenia-at-the-ascpt-2024-annual-meeting

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical co...

 hc-wainwright--co-reiterates-buy-on-reviva-pharmaceuticals-maintains-20-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains ...

 hc-wainwright--co-reiterates-buy-on-reviva-pharmaceuticals-maintains-20-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains ...

 reviva-to-host-kol-event-to-discuss-topline-data-from-phase-3-recover-trial-of-brilaroxazine-in-schizophrenia

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical co...

 reviva-provides-corporate-and-program-updates-and-highlights-key-upcoming-milestones

– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open ...

 hc-wainwright--co-reiterates-buy-on-reviva-pharmaceuticals-maintains-20-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains ...

 reviva-pharmaceuticals-q3-eps-044-misses-037-estimate

Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate...

 hc-wainwright--co-maintains-buy-on-reviva-pharmaceuticals-raises-price-target-to-20

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and raises the ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION